Fatty liver disease
Nature Outline: Fatty liver disease
The worldwide rise in obesity and diabetes has led to a massive spike in the number of people with non-alcoholic fatty liver disease, which often advances to a more severe condition known as non-alcoholic steatohepatitis, and in some cases to fibrosis and cirrhosis. This Outline discusses new ways to diagnose and treat this progressive condition.
Nature Outline: Fatty liver disease is an editorially independent supplement to Nature produced with the financial support from a third party. About this content.
Nature is pleased to acknowledge financial support from Gilead Sciences in producing this Outline. The sponsor retains sole responsibility for the following messages.
For 30 years, Gilead has worked to develop medicines that address areas of unmet medical need for people around the world.
Gilead’s medicines and pipeline of investigational drugs include treatments for HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular conditions.
